文献速递湿疹皮炎与荨麻疹

评估甲氨蝶呤与环孢素治疗儿童重度特应性湿疹的有效性、安全性和成本效果的随机对照试验方案:重度特应性湿疹治疗试验(TREAT)

A randomized controlled trial protocol assessing the effectiveness, safety and cost-effectiveness of methotrexate vs. ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe Atopic eczema Trial (TREAT).
PubMed 文献 · Br J Dermatol · 2018-10-28

本研究为多中心、平行组、评估者盲法、实用性随机对照试验,计划纳入102例2-16岁中度至重度特应性湿疹患儿,按1:1随机接受甲氨蝶呤(0.4 mg/kg/周)或环孢素(4 mg/kg/天)治疗36周并随访24周,主要结局为12周时o-SCORAD评分变化及停药后首次显著发作时间。

要点

  • 甲氨蝶呤与环孢素治疗儿童重度特应性湿疹的头对头随机对照试验方案。
  • 计划纳入102例2-16岁患儿,随机接受甲氨蝶呤0.4 mg/kg/周或环孢素4 mg/kg/天。
  • 主要结局为12周o-SCORAD评分变化及停药后首次显著发作时间。

核心结论

  • 该试验针对系统综述和治疗指南中强调的重要治疗问题,试验设计为实用性以反映当前临床实践。

研究设计与样本

  • 多中心、平行组、评估者盲法、实用性随机对照试验,持续36周,随访24周。
  • 计划纳入102例2-16岁中度至重度特应性湿疹患儿,对局部治疗无应答,按1:1随机接受甲氨蝶呤(0.4 mg/kg/周)或环孢素(4 mg/kg/天)。

主要发现

  • 该试验方案尚未报告结果。

关键数值与推荐

  • 主要结局为基线至12周时客观特应性皮炎严重程度评分(o-SCORAD)的变化,以及治疗停止后至首次显著发作的时间。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oral systemic immunomodulatory medication is regularly used off-licence in children with severe atopic eczema. However, there is no firm evidence regarding the effectiveness, safety, cost-effectiveness and impact on quality of life from an adequately powered randomized controlled trial (RCT) using systemic medication in children. OBJECTIVES: To assess whether there is a difference in the speed of onset, effectiveness, side-effect profile and reduction in flares post-treatment between ciclosporin (CyA) and methotrexate (MTX), and also the cost-effectiveness of the drugs. Treatment impact on quality of life will also be examined in addition to whether FLG genotype influences treatment response. In addition, the trial studies the immune-metabolic effects of CyA and MTX. METHODS: Multicentre, parallel group, assessor-blind, pragmatic RCT of 36 weeks' duration with a 24-week follow-up period. In total, 102 children aged 2-16 years with moderate-to-severe atopic eczema, unresponsive to topical treatment will be randomized (1 : 1) to receive MTX (0·4 mg kg-1 per week) or CyA (4 mg kg-1 per day). RESULTS: The trial has two primary outcomes: change from baseline to 12 weeks in Objective Severity Scoring of Atopic Dermatitis (o-SCORAD) and time to first significant flare following treatment cessation. CONCLUSIONS: This trial addresses important therapeutic questions, highlighted in systematic reviews and treatment guidelines for atopic eczema. The trial design is pragmatic to reflect current clinical practice.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Irvine AD, Jones AP, Beattie P, et al. A randomized controlled trial protocol assessing the effectiveness, safety and cost-effectiveness of methotrexate vs. ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe Atopic eczema Trial (TREAT). Br J Dermatol. 2018. PMID: 29727479. doi:10.1111/bjd.16717

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。